These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 10194039

  • 1. Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine.
    Hausen B, Boeke K, Berry GJ, Segarra IT, Christians U, Morris RE.
    J Heart Lung Transplant; 1999 Feb; 18(2):150-9. PubMed ID: 10194039
    [Abstract] [Full Text] [Related]

  • 2. Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability.
    Hausen B, Ikonen T, Briffa N, Berry GJ, Christians U, Robbins RC, Hook L, Serkova N, Benet LZ, Schuler W, Morris RE.
    Transplantation; 2000 Jan 15; 69(1):76-86. PubMed ID: 10653384
    [Abstract] [Full Text] [Related]

  • 3. Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment.
    Hausen B, Boeke K, Berry GJ, Segarra I, Benet LZ, Christians U, Morris RE.
    Transplantation; 1999 Apr 15; 67(7):956-62. PubMed ID: 10221478
    [Abstract] [Full Text] [Related]

  • 4. Successful treatment of acute, ongoing rat lung allograft rejection with the novel immunosuppressant SDZ-RAD.
    Hausen B, Boeke K, Berry GJ, Christians U, Schüler W, Morris RE.
    Ann Thorac Surg; 2000 Mar 15; 69(3):904-9. PubMed ID: 10750781
    [Abstract] [Full Text] [Related]

  • 5. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin.
    Hausen B, Gummert J, Berry GJ, Christians U, Serkova N, Ikonen T, Hook L, Legay F, Schuler W, Schreier MH, Morris RE.
    Transplantation; 2000 Feb 27; 69(4):488-96. PubMed ID: 10708100
    [Abstract] [Full Text] [Related]

  • 6. Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation.
    Schuurman HJ, Ringers J, Schuler W, Slingerland W, Jonker M.
    Transplantation; 2000 Mar 15; 69(5):737-42. PubMed ID: 10755519
    [Abstract] [Full Text] [Related]

  • 7. Potentiation of immunosuppressive efficacy by combining the novel leflunomide analog, HMR 279, with microemulsion cyclosporine in a rat lung transplant model.
    Hausen B, Boeke K, Berry GJ, Gummert JF, Christians U, Morris RE.
    Transplantation; 1999 Feb 15; 67(3):354-9. PubMed ID: 10030278
    [Abstract] [Full Text] [Related]

  • 8. Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine.
    Serkova N, Hausen B, Berry GJ, Jacobsen W, Benet LZ, Morris RE, Christians U.
    J Pharmacol Exp Ther; 2000 Jul 15; 294(1):323-32. PubMed ID: 10871329
    [Abstract] [Full Text] [Related]

  • 9. Sirolimus (rapamycin) potentiates cyclosporine in prevention of acute lung rejection.
    Longoria J, Roberts RF, Marboe CC, Stouch BC, Starnes VA, Barr ML.
    J Thorac Cardiovasc Surg; 1999 Apr 15; 117(4):714-8. PubMed ID: 10096966
    [Abstract] [Full Text] [Related]

  • 10. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts.
    Viklický O, Zou H, Müller V, Lacha J, Szabó A, Heemann U.
    Transplantation; 2000 Feb 27; 69(4):497-502. PubMed ID: 10708101
    [Abstract] [Full Text] [Related]

  • 11. Early clinical experience with a novel rapamycin derivative.
    Nashan B.
    Ther Drug Monit; 2002 Feb 27; 24(1):53-8. PubMed ID: 11805723
    [Abstract] [Full Text] [Related]

  • 12. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine.
    Schuurman HJ, Cottens S, Fuchs S, Joergensen J, Meerloo T, Sedrani R, Tanner M, Zenke G, Schuler W.
    Transplantation; 1997 Jul 15; 64(1):32-5. PubMed ID: 9233697
    [Abstract] [Full Text] [Related]

  • 13. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo.
    Schuler W, Sedrani R, Cottens S, Häberlin B, Schulz M, Schuurman HJ, Zenke G, Zerwes HG, Schreier MH.
    Transplantation; 1997 Jul 15; 64(1):36-42. PubMed ID: 9233698
    [Abstract] [Full Text] [Related]

  • 14. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients.
    Neumayer HH, Paradis K, Korn A, Jean C, Fritsche L, Budde K, Winkler M, Kliem V, Pichlmayr R, Hauser IA, Burkhardt K, Lison AE, Barndt I, Appel-Dingemanse S.
    Br J Clin Pharmacol; 1999 Nov 15; 48(5):694-703. PubMed ID: 10594471
    [Abstract] [Full Text] [Related]

  • 15. Synergism of RAD and cyclosporin A in prevention of acute rat corneal allograft rejection.
    Reis A, Megahed M, Reinhard T, Godehardt E, Braunstein C, Sundmacher R.
    Cornea; 2002 Jan 15; 21(1):81-4. PubMed ID: 11805513
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of SDZ RAD compared with CsA monotherapyand combined Rad/FTY720 treatment in a murine cardiac allotransplantation model.
    Nikolova Z, Hof A, Baumlin Y, Hof RP.
    Transpl Immunol; 2001 Oct 15; 9(1):43-9. PubMed ID: 11680571
    [Abstract] [Full Text] [Related]

  • 17. Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. The U.K. Neoral Renal Study Group.
    Pollard SG, Lear PA, Ready AR, Moore RH, Johnson RW.
    Transplantation; 1999 Nov 15; 68(9):1325-31. PubMed ID: 10573071
    [Abstract] [Full Text] [Related]

  • 18. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group.
    Keown P, Niese D.
    Kidney Int; 1998 Sep 15; 54(3):938-44. PubMed ID: 9734620
    [Abstract] [Full Text] [Related]

  • 19. Leflunomide prolongs pulmonary allograft and xenograft survival.
    Yuh DD, Gandy KL, Morris RE, Hoyt G, Gutierrez J, Reitz BA, Robbins RC.
    J Heart Lung Transplant; 1995 Sep 15; 14(6 Pt 1):1136-44. PubMed ID: 8719461
    [Abstract] [Full Text] [Related]

  • 20. RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection.
    Kahan BD, Kaplan B, Lorber MI, Winkler M, Cambon N, Boger RS.
    Transplantation; 2001 May 27; 71(10):1400-6. PubMed ID: 11391226
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.